Germany
· Delayed Price · Currency is EUR Northwest Biotherapeutics Statistics
Total Valuation
BST:NBYB has a market cap or net worth of EUR 278.26 million. The enterprise value is 341.88 million.
| Market Cap | 278.26M |
| Enterprise Value | 341.88M |
Important Dates
The next estimated earnings date is Wednesday, May 13, 2026.
| Earnings Date | May 13, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 1.63B |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +17.26% |
| Shares Change (QoQ) | +2.90% |
| Owned by Insiders (%) | 2.27% |
| Owned by Institutions (%) | 0.05% |
| Float | 1.59B |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 237.09 |
| PB Ratio | -6.87 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -6.53 |
| EV / Sales | 290.52 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -8.68 |
Financial Position
The company has a current ratio of 0.06
| Current Ratio | 0.06 |
| Quick Ratio | 0.03 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | -1.40 |
| Interest Coverage | -6.89 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -69.33% |
| Return on Invested Capital (ROIC) | -1,310.00% |
| Return on Capital Employed (ROCE) | 575.54% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | 11,178 |
| Profits Per Employee | -498,666 |
| Employee Count | 105 |
| Asset Turnover | 0.03 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -457,363 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -41.84% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -41.84% |
| 50-Day Moving Average | 0.18 |
| 200-Day Moving Average | 0.21 |
| Relative Strength Index (RSI) | 45.04 |
| Average Volume (20 Days) | 11,530 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 25.07 |
Income Statement
In the last 12 months, BST:NBYB had revenue of EUR 1.17 million and -52.36 million in losses. Loss per share was -0.04.
| Revenue | 1.17M |
| Gross Profit | -23.34M |
| Operating Income | -51.03M |
| Pretax Income | -51.70M |
| Net Income | -52.36M |
| EBITDA | -49.27M |
| EBIT | -51.03M |
| Loss Per Share | -0.04 |
Balance Sheet
The company has 2.59 million in cash and 55.21 million in debt, giving a net cash position of -52.62 million.
| Cash & Cash Equivalents | 2.59M |
| Total Debt | 55.21M |
| Net Cash | -52.62M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | -40.52M |
| Book Value Per Share | -0.03 |
| Working Capital | -73.40M |
Cash Flow
In the last 12 months, operating cash flow was -38.12 million and capital expenditures -1.28 million, giving a free cash flow of -39.41 million.
| Operating Cash Flow | -38.12M |
| Capital Expenditures | -1.28M |
| Depreciation & Amortization | 1.76M |
| Net Borrowing | 25.59M |
| Free Cash Flow | -39.41M |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | -4,347.89% |
| Pretax Margin | -4,404.86% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
BST:NBYB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -17.26% |
| Shareholder Yield | -17.26% |
| Earnings Yield | -18.82% |
| FCF Yield | -14.16% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
BST:NBYB has an Altman Z-Score of -27.86 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -27.86 |
| Piotroski F-Score | 4 |